Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as...

Descripción completa

Detalles Bibliográficos
Autores principales: Nami, Babak, Maadi, Hamid, Wang, Zhixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210751/
https://www.ncbi.nlm.nih.gov/pubmed/30241301
http://dx.doi.org/10.3390/cancers10100342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210751/
https://www.ncbi.nlm.nih.gov/pubmed/30241301
http://dx.doi.org/10.3390/cancers10100342

Ejemplares similares